Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.08 -	0.01 89.85%	0.00 96.09%	1.28 408,195.95%	5.99 368.06%	3.48 41.96%	0.64 81.66%
company equity multiplier	-0.05 -	-0.01 86.93%	-0.13 1,839.78%	1.08 926.62%	1.03 3.98%	1.27 23.02%	-1.32 203.56%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.00 -	1.00 0.00%	0.62 38.27%	0.82 33.28%	1.00 21.15%	0.99 0.37%	1 0.72%
effective tax rate		0.00 -	0.70 378,716.81%	0.22 68.51%	0.00 98.43%	0.01 108.64%
enterprise value multiple	-61.25 -	-59.05 3.59%	-72.49 22.76%	-7.24 90.01%	-6.10 15.79%	-3.18 47.75%	-2.90 8.94%
fixed asset turnover
free cash flow per share	-0.12 -	-0.13 3.81%	-0.08 36.68%	-0.63 682.85%	-1.20 90.26%	-2.12 77.13%	-4.43 108.83%
gross profit margin
interest coverage	-8.12K -	-10.82K 33.15%	0.04 100.00%	-0.14 458.46%		139.63 -
inventory turnover
long term debt to capitalization			-0.06 -
net income per ebt	1 -	1 0%	0.30 70.05%	0.78 160.21%	1.00 27.85%	0.99 0.38%	1 0.73%
net profit margin
operating cash flow per share	-0.12 -	-0.13 3.81%	-0.08 36.68%	-0.63 682.85%	-1.20 90.26%	-2.12 77.13%	-4.43 108.83%
operating profit margin
payables turnover
pretax profit margin
price fair value	-6.05 -	-5.56 8.17%	-6.63 19.29%	6.31 195.18%	3.01 52.23%	3.87 28.45%	-21.77 662.48%
receivables turnover
return on assets	-1.91 -	-14.00 634.43%	-0.27 98.10%	-0.52 97.33%	-0.31 40.15%	-0.70 122.43%	-5.51 688.71%
return on capital employed	5.16 -	1.38 73.23%	1.80 30.10%	-0.88 149.01%	-0.33 62.90%	-0.90 175.69%	-9.48 952.43%
return on equity	0.10 -	0.09 4.04%	0.03 63.18%	-0.56 1,731.18%	-0.32 42.53%	-0.89 173.62%	7.25 916.77%
total debt to capitalization			-0.06 -

NYSE:ANVS

Annovis Bio, Inc.

Last Close

8.61

08/11 21:00

Market Cap

134.95M

Beta: 1.21

Volume Today

269.81K

Avg: 104.10K

PE Ratio

−1.56

PFCF: −3.22

Preview